about
Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesisThe role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trialGuidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromesSafety and efficacy of fondaparinux as an adjunctive treatment to thrombolysis in patients with high and intermediate risk pulmonary embolism.[Guidelines on the diagnosis and management of acute pulmonary embolism].Universal definition of myocardial infarction.Rivaroxaban in patients with a recent acute coronary syndrome.Third universal definition of myocardial infarction.Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry.The need for resources for clinical research: proceedings of a policy conference held at the European Heart House, 27-28 June 2002: executive summary.Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia--Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents.The potential value of intravascular ultrasound imaging in diagnosis of aortic intramural hematomaQuality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.Managing cardiovascular risk in patients with metabolic syndrome.The number of circulating CD14(+) cells is related to infarct size and postinfarct volumes in ST segment elevation myocardial infarction but not non-ST segment elevation myocardial infarction.International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries.Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes.Efficacy and safety of fondaparinux in patients with acute coronary syndromes.Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group.Current antithrombotic agents for acute coronary syndromes: focus on bleeding risk.Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation.Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology.The need for resources for clinical research: the European Society of Cardiology calls for European, international collaboration.Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.Tolerability of percutaneous coronary interventions in patients receiving nadroparin calcium for unstable angina or non-Q-wave myocardial infarction: the Angiofrax study.Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.Routine use of fondaparinux in acute coronary syndromes: a 2-year multicenter experience.Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes.Reperfusion strategy in Europe: temporal trends in performance measures for reperfusion therapy in ST-elevation myocardial infarction.Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial.[Platelet antiaggregation treatment in the aftermath of GUSTO IV, TARGET, TACTICS, and CURE trials].Changes in management of elderly patients with myocardial infarction.Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study.
P50
Q26827384-CB9586F1-F8AF-482E-B3E0-47A428F66AC6Q28267043-C6E2549C-0531-494B-B075-D1EDE060BDA4Q28292426-859D4576-9357-4219-A19F-7C78C784775DQ28306261-3E2170CE-5342-4294-B427-E7BBBB4003A3Q33156769-906BB017-A9B4-42F4-A294-CF6A90F30347Q33470505-5E93C549-859B-4623-8922-B3600C55CDC6Q34007701-DC066AFA-8CC2-4332-ADF0-0638DE6E418CQ34231902-FE52C3B5-8F68-411C-8E28-2B00C06B0B4CQ34295914-FFD3E13B-00CB-41AB-9BE0-401091392136Q34737465-5162754F-355A-41DF-93BF-B9A0B2284FDBQ35153784-23C8F1A6-0E91-4596-9119-272BC01F6195Q35605494-C7CAAEA7-4FD8-4D61-9330-65F92DCFE9FDQ35768553-3CA4EF9B-63DB-4414-BFAC-B5FA3467FE28Q36077350-A00C1314-417F-47FA-912A-3320FD26262BQ36177155-685A2079-9DCF-4EAA-B57C-990D1A048811Q36563115-CE1133AB-B05E-4835-B6AD-17B2A71A2886Q36772320-972ABAC5-F523-4C98-B9AA-1FAC05DEB758Q36777590-6A12CCAA-DED9-4D57-8902-1F84CF9EA62BQ36800606-3D340EC7-0993-4615-A883-7A136910268DQ37012898-DB301113-6554-428E-B2F5-243E1A5D79AFQ37627206-DA861F00-75CD-4F46-A12A-CC3851FF00FDQ37643905-28F76ADD-FDD1-4620-AC7A-DE6F0E754A76Q37958434-4867156B-DC00-4BFB-8C55-413BCEC948F8Q38408470-E9B3EBC4-1278-4931-BCF6-ACB1B0F848D4Q38415694-8BFBBFC5-1324-46BE-80F6-93407544A056Q38448455-40A85BD8-F643-445B-8580-9B4CBB450455Q39734057-24762933-E51B-4A7B-83C0-6A61BA6ACB36Q40615880-BF5CF99D-4A02-4AB2-AC17-ADA96EEC7771Q42025980-2C279BD9-4366-49AE-A334-7070357B9AEFQ42598937-3FFA548B-1394-48C4-852C-45D1BCBEFF32Q42604256-BE9B9152-33F8-4B7F-84A4-B00B890BB69DQ42917068-12806B3F-F40F-4388-AFEB-74C252A7480DQ42917584-498D29A3-D6C8-4203-8021-C3386BA063C5Q43163871-F8D1A3B4-3D85-4425-90B1-8FE67881FA5DQ43262262-B080EE03-4FBE-4E0C-B519-49C16DDF4DFDQ43453130-96AEBEF7-B53D-4F05-AA95-523C6BEAFEDDQ43952384-6B434665-2290-456F-AAF7-8A981609CCECQ44061245-7327FB28-5B38-4FE3-BA3D-7614B4465E41Q44129987-148253EC-B4ED-43E1-A306-91BFCA0C34CBQ44145226-A5349865-E79D-413E-A44D-748AB6D70605
P50
name
Jean-Pierre Bassand
@en
type
label
Jean-Pierre Bassand
@en
prefLabel
Jean-Pierre Bassand
@en